(MEIL) Finalizing Supply For Up To 40 Railcars Of Biodiesel/Month to U.S.

(EXEL) Announces Presentation of Final Phase 1b Data for Cobimetinib

Exelixis, Inc. (NASDAQ:EXEL) today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis’ collaborator and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAF^V600 mutation. Antoni Ribas, M.D., Ph.D., a professor in the department of medicine at Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, presented the data during a plenary session today at the 10^th European Association of Dermato-Oncology (EADO) Congress. The meeting is taking place from May 7-10, 2014, in Vilnius, Lithuania.

“Building on the previous data from the BRIM7 trial, these final results provide encouraging signs of clinical activity in BRAFi-naïve patients with the combination of cobimetinib and vemurafenib,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “We are pleased with the progress Roche has made in investigating cobimetinib, an Exelixis-discovered compound, in this patient population. People with this disease still urgently need improved treatment options, and we look forward to the top-line data from coBRIM, the ongoing phase 3 pivotal trial, anticipated later this year.”

Study Design

The phase 1b dose escalation study was designed to evaluate the safety and tolerability of cobimetinib in combination with vemurafenib. The dose escalation stage of the trial comprised 10 dosing cohorts of 3-6 patients and evaluated three different dosing schedules of cobimetinib in combination with twice daily administration of vemurafenib. After the maximum tolerated dose (MTD) was defined, two dose cohorts were expanded and additional patients with BRAF-mutated melanoma who were either BRAFi-naïve or vemurafenib-progressing patients were accrued.

Study Results

As of October 1st, 2013, 129 patients had been treated, comprising 66 patients who had previously progressed while receiving vemurafenib and 63 patients who were BRAFi-naïve. Of the 63 BRAFi-naïve patients, 43 (68%) were previously untreated and 20 (32%) had been treated with agents other than a BRAFi. The majority of the patients had Stage IV, M1c melanoma at the time of enrollment (vemurafenib-progressors 82%, BRAFi-naïve 70%). The median duration of follow-up in vemurafenib-progressor and BRAFi-naïve patients was 6.3 and 12.7 months, respectively.

The final results of the exploratory secondary endpoints of BRIM7 showed anti-tumor activity for the combination of cobimetinib and vemurafenib. In BRAFi-naïve patients (n=63), an 87% confirmed overall response rate (ORR) was achieved, including 10% complete responses and 78% partial responses. An additional 10% of patients achieved stable disease. The majority of tumor responses were observed within the first six weeks following initiation of treatment. The median progression free survival (PFS) for BRAFi-naïve patients was 13.7 months. Results for vemurafenib-progressor patients (n=66) showed a 15% confirmed ORR, 42% stable disease rate, and median PFS of 2.8 months. The median overall survival (OS) for BRAFi-naïve patients had not been reached, with a 1 year survival estimate of 83%. For the vemurafenib-progressor patients the median OS was 8.3 months with an estimated 1 year survival of 32%.

Safety

The most common adverse events (AEs) regardless of attribution to study treatment in the 129 patients treated to date were non-acneiform rash, diarrhea, fatigue, photosensitivity/sunburn, liver laboratory abnormalities and nausea. The most common (all Grade; ≥ Grade 3) AEs in BRAFi-naïve patients were non-acneiform rash (87%; 14%) diarrhea (83%; 8%), fatigue (70%; 10%) photosensitivity/sunburn (67%; 3%), liver laboratory abnormality (67%, 19%) and nausea (57%; 3%). The most common (all Grade; ≥ Grade 3) AEs in vemurafenib-progressor patients were diarrhea (47%; 3%), nausea (33%; 3%), non-acneiform rash (33%; 2%), fatigue (27%; 2%) and liver laboratory abnormality (33%; 6%). Most adverse events were mild to moderate in severity. Permanent discontinuation of vemurafenib, cobimetinib or the combination due to AEs was infrequent, and occurred in 5% (vemurafenib), 2% (cobimetinib) and 2% (combination) of the vemurafenib progressing patients and 6% (vemurafenib), 5% (cobimetinib) and 3% (combination) of the BRAFi-naïve patients.

About the Phase 3 Pivotal Trial coBRIM

coBRIM is the multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating the combination of vemurafenib with cobimetinib versus vemurafenib in previously untreated BRAF^V600 mutation positive patients with unresectable locally advanced or metastatic melanoma. The trial is fully enrolled and data are expected to be available in 2014.

About Cobimetinib

Cobimetinib (formerly GDC-0973/XL518) is an inhibitor of MEK, a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. In preclinical studies, oral dosing of cobimetinib resulted in sustained inhibition of MEK in RAS or BRAF mutant tumor models. Cobimetinib is being developed by Roche and Genentech, a member of the Roche Group, under a collaboration with Exelixis.

About the Collaboration

Exelixis discovered cobimetinib internally and advanced the compound to investigational new drug (IND) status. In late 2006, Exelixis entered into a worldwide co-development agreement with Genentech, under which Exelixis received initial upfront and milestone payments for signing the agreement and submitting the IND. Exelixis was responsible for development of cobimetinib through the end of phase 1, at which point Genentech exercised its option to further develop the compound.

Exelixis is entitled to an initial equal share of U.S. profits and losses, which will decrease as sales increase, and will share equally in the U.S. marketing and commercialization costs. Exelixis is eligible to receive royalties on net sales of the product outside the United States. In December 2012, Exelixis announced that it exercised its option to co-promote cobimetinib in the United States.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company’s web site at www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: the continued development and clinical and therapeutic potential of cobimetinib; anticipated developments with respect to coBRIM, including the expected availability of top-line data therefrom; the designs, plans and goals for BRIM7 and coBRIM; the plan of Genentech and Exelixis to share U.S. profits and losses for cobimetinib and U.S. marketing and commercialization costs for cobimetinib; and Exelixis’ potential receipt of royalties on net sales of cobimetinib products outside the United States. Words such as “provide,” “encouraging,” “investigating,” “look forward,” “anticipated,” “designed,” “expected,” “available,” “entitled,” “share,” “will,” “potential,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Exelixis’ actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to the potential failure of cobimetinib to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of cobimetinib; Exelixis’ dependence on its relationship with Genentech/Roche and Exelixis’ ability to maintain its rights under the collaboration; the uncertainty of regulatory approval processes; market competition; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in Exelixis’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 1, 2014 and in Exelixis’ other filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

(BTX) LifeMap to Develop Mobile Health Products

BioTime, Inc. (NYSE MKT:BTX) announced today that its subsidiary LifeMap Sciences, Inc., a technology leader in online biomedical information, has created LifeMap Solutions, Inc., a medical technology startup focused on creating innovative mobile health (mHealth) products and services powered by biomedical and other personal big data. The initial planned product is envisioned to provide information based on interpretations of one or more components of clinical data and other information of individuals, including genetic information if provided, relating to human disease, health or wellness.

LifeMap Solutions will collaborate with the Icahn School of Medicine at Mount Sinai to develop the new personal mHealth products. While detailed product plans were not revealed at this time, the company disclosed that the planned products are interactive mobile applications that will connect users with their complex personal health information and other big data. LifeMap Solutions will co-locate core members of its product development team within Mount Sinai to work alongside research and development personnel led by Dr. Eric Schadt, Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. The primary focus of Mount Sinai in the product development collaboration will relate to the development of a software engine. LifeMap Solutions will be responsible for developing the entire technology platform, including server and client components. However, both parties will participate in the planning and development of all aspects of the integrated software system.

The initial financing tranche for LifeMap Solutions will be provided to LifeMap Sciences by BioTime through the purchase of additional shares of LifeMap Sciences common stock. BioTime may acquire additional LifeMap Sciences common stock for cash or in exchange for BioTime common shares when product development milestones are met and if funding is not provided through other sources. Additionally, Mount Sinai will defray a portion of the initial development cost of the project by providing services of its personnel and use of its facilities at a reduced cost.

“The creation of LifeMap Solutions represents a strategic step along BioTime’s path towards extending LifeMap’s leadership in online genomic and medical information,” said Dr. Michael West, CEO of BioTime. “We share with Dr. Schadt a vision of new products and services designed to markedly enhance the public’s access to big data and to improve quality of life.”

Corey Bridges, a Silicon Valley veteran, will serve as LifeMap Solutions’ Chief Executive Officer. Over the past two decades, Mr. Bridges has overseen the market introductions of several innovative technology companies, including Netflix, Inc., Zone Labs, and The Multiverse Network, Inc. A pre-IPO employee at Netscape, he launched several ground-breaking Internet products internationally, and years later launched James Cameron’s CAMERON | PACE Group in China and Europe.

About BioTime, Inc.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime’s therapeutic and research products include a wide array of proprietary PureStem^® progenitors, HyStem^® hydrogels, culture media, and differentiation kits. BioTime is developing Renevia™ (a HyStem^® product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend^®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend^® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

• Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine.

• OncoCyte Corporation is developing products and technologies to diagnose and treat cancer.

• Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.

• LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and distributes GeneCards^®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery^® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.

• ES Cell International Pte Ltd., a Singapore private limited company, developed clinical and research grade hES cell lines and plans to market those cell lines and other BioTime research products in over-seas markets as part of BioTime’s ESI BIO Division.

• BioTime Asia, Limited, a Hong Kong company, may offer and sell products for research use for BioTime’s ESI BIO Division.

• OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries.

• ReCyte Therapeutics, Inc. is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.

Additional information about BioTime can be found on the web at www.biotimeinc.com

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on its Integrated Biomedical Knowledgebase and discovery platform for biomedical research, which currently includes GeneCards^®, the leading human gene database; LifeMap Discovery^®, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap’s products are used in many institutions including academia, research hospitals, patent offices, and leading biotechnology and pharmaceutical companies. In addition to its currently marketed products, LifeMap is pursuing several new internet and informatics products with substantial rapid revenue growth potential, leveraging its existing products and their large user base.

About LifeMap Solutions, Inc.

LifeMap Solutions is developing innovative mobile health technology in partnership with the Icahn Institute for Genomics and Multiscale Biology, which is located within the Icahn School of Medicine at Mount Sinai. LifeMap Solutions is a subsidiary of LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. that is developing an integrated resource for biomedical and stem cell research. LifeMap Solutions is headquartered in Alameda, California. For more information, please visit www.lifemap-solutions.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

(MDLZ) & D.E Master Blenders 1753 Form World’s Leading Pure-Play Coffee Company

– Partnership Will Combine Jacobs and Tassimo with Douwe Egberts and Senseo in Portfolio of Iconic Coffee Brands – Compelling Strategic Fit Due to Highly Complementary Brands, Geographic Profile and Technology Platforms – Combined Company to Capitalize on Significant Global Growth Opportunities through Increased Scale, Greater Focus and Targeted Investment

DEERFIELD, Ill. and AMSTERDAM, May 7, 2014  — Mondelez International, Inc. (NASDAQ: MDLZ) and D.E Master Blenders 1753 B.V. today announced their intention to combine their respective coffee businesses to create the world’s leading pure-play coffee company, with annual revenues of more than $7 billion (€5 billion) and an EBITDA[1] margin in the high teens.

The new company, to be called Jacobs Douwe Egberts (JDE), will be based in the Netherlands.  It will hold leading market positions in more than two dozen countries and have a strong emerging market presence, giving it significant revenue synergy opportunities in the $81 billion global coffee category [2]. The two companies own some of the world’s leading coffee brands, such as Jacobs, Carte Noire, Gevalia, Kenco, Tassimo and Millicano from Mondelez International and Douwe Egberts, L’OR, Pilao and Senseo from D.E Master Blenders 1753.

“Jacobs Douwe Egberts will leverage the rich histories of both companies, combining our complementary geographic footprints, portfolios of iconic brands and innovative technologies to offer more people around the world more access to high-quality coffee and allowing the company to capitalize on the significant growth opportunities in a highly attractive market,” said Pierre Laubies, CEO of D.E Master Blenders 1753 and prospective CEO of the combined company.

“We’re delighted with this transaction and the substantial value we expect to create for our shareholders,” said Irene Rosenfeld, Chairman and CEO of Mondelez International, whose coffee portfolio has outpaced market growth since 2010, thanks to innovations such as the Tassimo multibeverage on-demand brewing system and Millicano wholebean instant coffee.  “By retaining a significant stake in the combined company, we’ll continue to benefit from the future growth of the coffee category and share in the synergies and tremendous upside of this leading, one-of-a-kind coffee company.”

Transaction Summary

The parties have entered into an agreement to combine Mondelez International’s wholly owned coffee portfolio (outside of France) with D.E Master Blenders 1753. In conjunction with this transaction, Acorn Holdings B.V. (“AHBV”), owner of D.E Master Blenders 1753, has made a binding offer to receive Mondelez International’s coffee business in France. The parties have also invited Mondelez International’s partners in certain joint ventures to join the new company. The transactions remain subject to regulatory approvals and the completion of employee information and consultation requirements.

In 2013, Mondelez International’s wholly owned coffee business generated approximately $3.9 billion (€2.9 billion) in revenue, and D.E Master Blenders 1753 generated approximately $3.4 billion (€2.5 billion) in revenue.

Upon completion of all proposed transactions, Mondelez International will receive cash of approximately $5 billion and a 49 percent equity interest in Jacobs Douwe Egberts.  AHBV will hold a majority share in the proposed combined company and will have a majority of the seats on the Board, which will be chaired by current D.E Master Blenders 1753 Chairman Bart Becht.  AHBV is owned by an investor group led by JAB Holding Company s.a r.l.  Mondelez International will have certain minority rights.

The transactions are expected to be completed in the course of 2015, subject to limited closing conditions, including regulatory approvals.  During this time, Mondelez International and D.E Master Blenders 1753 will undertake consultations with all Works Councils and employee representatives as required in connection with the transactions.

The new company’s executive leadership team will be named at a later date and will consist of executives from both D.E Master Blenders 1753 and Mondelez International.  Fact sheets with key data about the coffee businesses of both companies are available for download at http://bit.ly/1iiBeFe.

About D.E Master Blenders 1753

D.E Master Blenders 1753 is a leading pure-play coffee and tea company that offers an extensive range of high-quality, innovative products through well-known brands such as Douwe Egberts, Senseo, L’OR, Pilao, Merrild, Moccona, Pickwick and Tea Forte in both retail and out of home markets. The company holds a number of leading market positions across Europe, Brazil, Australia and Thailand and its products are sold in more than 45 countries. D.E Master Blenders 1753 generated sales of more than €2.5 billion in 2013 and employs around 7,500 people worldwide. For more information, please visit www.demasterblenders1753.com.

About Mondelez International

Mondelez International, Inc. (NASDAQ: MDLZ) is a global snacking powerhouse, with 2013 revenue of $35 billion.  Creating delicious moments of joy in 165 countries, Mondelez International is a world leader in chocolate, biscuits, gum, candy, coffee and powdered beverages, with billion-dollar brands such as Cadbury, Cadbury Dairy Milk and Milka chocolate, Jacobs coffee, Oreo, LU and Nabisco biscuits, Tang powdered beverages and Trident gum. Mondelez International is a proud member of the Standard and Poor’s 500, NASDAQ 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com and www.facebook.com/mondelezinternational.

Forward-Looking Statements

This press release contains a number of forward-looking statements. Words, and variations of words, such as “will,” “expect,” “intend” and similar expressions are intended to identify these forward-looking statements, including, but not limited to, statements about: the parties’ entry into the transactions, the timeframe for completing the transactions and the financial and growth prospects for the new company; the cash proceeds and ownership interests to be received in the transactions; creation of value for shareholders; coffee category growth; and the benefits of the transactions to Mondelez International. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Mondelez International’s control, which could cause Mondelez International’s actual results to differ materially from those indicated in these forward-looking statements. Such factors include, but are not limited to, risks that the parties will fail to successfully complete the transactions on the anticipated timeframe and that the transactions will not yield the anticipated benefits. Please also see Mondelez International’s risk factors, as they may be amended from time to time, set forth in Mondelez International’s filings with the SEC, including its most recently filed Annual Report on Form 10-K. Mondelez International disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

[1] Earnings Before Interest, Taxes, Depreciation and Amortization

[2] Euromonitor, 2013

(QTWW) Technologies Discusses its Strategic Plans

LAKE FOREST, Calif., May 7, 2014  — Quantum Fuel Systems Technologies Worldwide, Inc. (NASDAQ: QTWW), a global leader in natural gas storage systems, integration and vehicle system technologies, announced its strategic direction to service the heavy duty OEM market segment, in addition to other market segments, with natural gas storage systems.  The Company recently announced a major long-term supply agreement with a major transportation company under which the Company will supply compressed natural gas (CNG) fuel storage tanks and module systems.  This new relationship is an early indicator of the Company’s ability to provide the industry with fully integrated systems and at the same time diversify its existing customer base by leveraging its core expertise in advanced tank technologies and systems integration and being a one-stop-shop for OEMs and fleets for complete CNG fuel systems.  The Company indicated that this strategy is the culmination of a careful and thought out plan over the past several months and is based on the Company’s desired direction, feedback from market participants seeking lower cost solutions, the Company’s technology advantages, and experience and capabilities of its personnel.

The Company has demonstrated its ability to develop cost-effective modules and systems around its industry leading tank technology for various vehicle applications, including heavy duty trucks.  During 2013, the Company introduced rail mounted storage systems for both medium duty and heavy duty trucks, and in March 2014 it introduced an innovative light-weight back-of-cab (BOC) storage system that was first showcased at a major truck exposition by Peterbilt.  These adaptable fuel storage module systems provide exceptional cost, weight and capacity per DGE (Diesel Gallon Equivalent) advantages compared to other competitive products.

Based on these product introductions, the Company has received strong interest for its BOC system and other derivative system configurations based on combining the Company’s rail mounted systems with its BOC system.  The Company is currently expanding its tank and CNG storage system production capacity for both rail mounted and BOC systems to meet third quarter production readiness. The Company will continue to provide key customers pre-production units leading up to the meaningful production levels targeted in the second half of calendar 2014.  The Company will also continue to leverage specific relationships to assemble and install these systems on vehicles in facilities and with companies already located next to OEM customers.

“We are currently positioned to take full advantage of our core strengths and provide complete fuel storage modules to the heavy duty and medium duty truck industry and provide exceptional value to our targeted customers,” commented Brian Olson, President and CEO of Quantum.  “We anticipate that the combination of our advanced tank technology and integration expertise, which we believe is unmatched in the industry, will drive significant levels of product orders from new customers in the coming months and that we are well positioned to be a significant supplier of fuel storage systems to the heavy duty trucking industry.”

The Company further stated in response to a recent announcement by Agility Fuel Systems, that Agility has an existing purchase order in place with the Company and both parties have communicated their intent to honor these arrangements and extend the purchase arrangement at least through December 31, 2014 to ensure uninterrupted deliveries to the existing customer base.

About Quantum: Quantum Fuel Systems Technologies Worldwide, Inc. is a leader in the innovation, development and production of natural gas fuel storage systems and the integration of vehicle system technologies including engine and vehicle control systems and drivetrains. Quantum produces one of the most innovative, advanced, and light‐weight compressed natural gas storage tanks in the world and supplies these tanks, in addition to fully‐integrated natural gas storage systems, to truck and automotive OEMs and aftermarket and OEM truck integrators. Quantum provides low emission and fast‐to‐market solutions to support the integration and production of natural gas fuel and storage systems, hybrid, fuel cell, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum is headquartered in Lake Forest, California, and has operations and affiliations in the United States, Canada, and India.

Forward Looking Statements: This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this report, other than those that are historical, are forward looking statements and can generally be identified by words such as “may,” “could,” “will,” “should,” “assume,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “predict,” “estimate,” “forecast,” “outlook,” “potential,” or “continue,” or the negative of these terms, and other comparable terminology. Examples of forward looking statements included in the press release include our anticipation that our combination of our advanced tank technology and integration expertise will drive significant levels of product orders from new customers in the coming months. Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements.  Such risks include the growth of the CNG market, market acceptance of the Company’s product and our ability to successfully compete as a supplier of complete CNG systems. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

More information about the products and services of Quantum can be found at http://www.qtww.com/ or you may contact:

Quantum Investor Relations
Phone:  949-399-4555
Email:  ir@qtww.com

(EA) Peggle Masters Rejoice – Peggle 2 Now Available for Xbox 360

PopCap Games, creator of some of the world’s most beloved video game franchises and a division of Electronic Arts Inc. (NASDAQ:EA), today announced Peggle™ 2 is now available as a digital download on the Xbox 360® videogame and entertainment system worldwide. Praised as “one of the best pick-up-and-play downloadable titles of the year” by Polygon, Peggle 2 is the whimsical puzzle game featuring the peg-popping greatness of the original with tons of new features and content.

“The joy of Peggle 2 is like a contagious fever…an Extreme Fever!” said John Vechey, General Manager at PopCap Games. “I can’t wait to share all the rainbows, joy, and unicorn horns to players on Xbox 360 and hope lots of new fans catch the fever!”

Peggle 2 offers 60 levels, 60 trials, 180 objectives, Peg Party multiplayer action, and four all-new Peggle Masters and power-ups at the price of $11.99, and is available now on Xbox Live. Peggle 2 on Xbox 360 will also include the brand-new multiplayer Duel Mode and colorblind option.

Just as in the classic original, Peggle 2 combines elements of pinball, pachinko and billiards and adds liberal doses of quirky fun, excitement and challenge – not to mention rainbows and a ninth of Beethoven!

For more information on Peggle 2, please visit: http://www.popcap.com/peggle-2. To join the conversation, like the game on Facebook and follow us on Twitter.

About PopCap

PopCap Games is the leading global developer, publisher and operator of casual video games: fun, easy-to-learn, captivating games that appeal to all ages across PC, mobile, social and other platforms. Based in Seattle, Washington, PopCap was founded in 2000, was acquired by Electronic Arts in 2011, and has studios in Seattle, San Francisco, Vancouver, and Shanghai.

About Electronic Arts

Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company delivers games, content and online services for Internet-connected consoles, personal computers, mobile phones and tablets. EA has more than 300 million registered players in over 200 countries.

In fiscal year 2014, EA posted GAAP net revenue of $3.6 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality blockbuster brands such as The Sims™, Madden NFL, EA SPORTS™ FIFA, Battlefield™, Dragon Age™ and Plants vs. Zombies™. More information about EA is available at www.ea.com/news.

EA SPORTS, The Sims, Dragon Age, Plants vs. Zombies and Battlefield are trademarks of Electronic Arts Inc. and its subsidiaries. John Madden, NFL and FIFA are the property of their respective owners and used with permission.

Xbox and Xbox 360 are trademarks of the Microsoft group of companies.

“The joy of Peggle 2 is like a contagious fever…an Extreme Fever!” said John Vechey, General Manager at PopCap Games. “I can’t wait to share all the rainbows, joy, and unicorn horns to players on Xbox 360 and hope lots of new fans catch the fever!”

Peggle 2 offers 60 levels, 60 trials, 180 objectives, Peg Party multiplayer action, and four all-new Peggle Masters and power-ups at the price of $11.99, and is available now on Xbox Live. Peggle 2 on Xbox 360 will also include the brand-new multiplayer Duel Mode and colorblind option.

Just as in the classic original, Peggle 2 combines elements of pinball, pachinko and billiards and adds liberal doses of quirky fun, excitement and challenge – not to mention rainbows and a ninth of Beethoven!

For more information on Peggle 2, please visit: http://www.popcap.com/peggle-2. To join the conversation, like the game on Facebook and follow us on Twitter.

About PopCap

PopCap Games is the leading global developer, publisher and operator of casual video games: fun, easy-to-learn, captivating games that appeal to all ages across PC, mobile, social and other platforms. Based in Seattle, Washington, PopCap was founded in 2000, was acquired by Electronic Arts in 2011, and has studios in Seattle, San Francisco, Vancouver, and Shanghai.

About Electronic Arts

Electronic Arts (NASDAQ: EA) is a global leader in digital interactive entertainment. The Company delivers games, content and online services for Internet-connected consoles, personal computers, mobile phones and tablets. EA has more than 300 million registered players in over 200 countries.

In fiscal year 2014, EA posted GAAP net revenue of $3.6 billion. Headquartered in Redwood City, California, EA is recognized for a portfolio of critically acclaimed, high-quality blockbuster brands such as The Sims™, Madden NFL, EA SPORTS™ FIFA, Battlefield™, Dragon Age™ and Plants vs. Zombies™. More information about EA is available at www.ea.com/news.

EA SPORTS, The Sims, Dragon Age, Plants vs. Zombies and Battlefield are trademarks of Electronic Arts Inc. and its subsidiaries. John Madden, NFL and FIFA are the property of their respective owners and used with permission.

Xbox and Xbox 360 are trademarks of the Microsoft group of companies.

(PEGI) Announces Commencement of Public Offering

Ross Marshall
Investor Relations
(416) 815-0700 ext. 238
rmarshall@tmxequicom.com

Matt Dallas
Media Relations
(917) 363-1333
matt.dallas@patternenergy.com

(AVGO) Completes Acquisition of LSI Corporation

SAN JOSE, Calif. and SINGAPORE, May 6, 2014  — Avago Technologies Limited (Nasdaq:AVGO) and LSI Corporation (Nasdaq:LSI), today announced Avago has completed its acquisition of LSI Corporation for $11.15 per share in an all-cash transaction valued at approximately $6.6 billion. The acquisition creates a highly diversified semiconductor market leader with approximately $5 billion in projected annual revenues.

Avago believes the acquisition of LSI positions Avago as a leader in the enterprise storage market. The acquisition also expands Avago’s product offerings and brings system-level expertise in its wired infrastructure market. With increased scale and a diversified product portfolio across multiple, attractive end markets, the combined company is strongly positioned to capitalize on the growing opportunities created by the rapid growth in data center IP and mobile data traffic.

In additional to the anticipated strategic benefits of the acquisition, Avago continues to anticipate achieving annual cost savings at a run rate of $200 million by the end of the fiscal year ending November 1, 2015, the first full fiscal year after closing. Avago’s management will discuss business outlook and provide guidance for the combined company during its second quarter earnings conference call on Thursday, May 29, 2014. Avago will include LSI Corporation’s contribution to financial performance in the company’s third quarter earnings announcement.

In connection with the closing of the acquisition, LSI’s common stock will cease to be publicly traded on the NASDAQ Stock Market after the close of market today.

About Avago Technologies Limited

Avago Technologies Limited is a leading designer, developer and global supplier of a broad range of analog semiconductor devices with a focus on III-V based products. Our product portfolio is extensive and includes thousands of products in three primary target markets: wireless communications, wired infrastructure and industrial & other.

About LSI Corporation

LSI Corporation designs semiconductors and software that accelerate storage and networking in datacenters, mobile networks and client computing. Our technology is the intelligence critical to enhanced application performance, and is applied in solutions created in collaboration with our partners. More information is available at www.lsi.com.

Cautionary Note Regarding Forward-Looking Statements

This announcement contains forward-looking statements, including statements by management, within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to (i) statements about the expected benefits of the acquisition of LSI Corporation (“LSI”), (ii) the combined organization’s plans, objectives, expectations and intentions with respect to future operations and products, (iii) the combined organization’s competitive position and opportunities, (iv) the impact of the transaction on the market for the combined organization’s products, (v) other statements identified by words such as “will”, “expect”, “intends”, “believe”, “anticipate”, “estimate”, “plan” and similar expressions. These forward-looking statements are based on current expectations, estimates, forecasts and projections of future Company or industry performance, based on management’s judgment, beliefs, current trends and market conditions, and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Accordingly, we caution you not to place undue reliance on these statements. Particular uncertainties that could materially affect future results include global economic conditions and concerns; cyclicality in the semiconductor industry or in our target markets; quarterly and annual fluctuations in operating results; loss of our significant customers; fluctuation in the timing and volume of customer demand; increased dependence on the volatile, wireless handset market and on the hard disk drive market; our competitive performance and ability to continue achieving design wins with our customers, as well as the timing of those design wins; market acceptance of the end products into which our products are designed; our ability to sell to new types of customers and to keep pace with technological advances; rates of growth in our target markets; our ability to achieve the growth prospects and synergies expected from acquisitions we may make, including our recent acquisition of LSI; delays, challenges and expenses associated with integrating acquired companies, including LSI, with our existing businesses; our dependence on contract manufacturing and outsourced supply chain and our ability to improve our cost structure through our manufacturing outsourcing program; prolonged disruptions of our or our contract manufacturers’ manufacturing facilities or other significant operations; our dependence on outsourced service providers for certain key business services and their ability to execute to our requirements; our ability to maintain or improve gross margin; our ability to maintain tax concessions in certain jurisdictions; our ability to protect our intellectual property and any associated increases in litigation expenses; dependence on and risks associated with distributors of our products; any expenses or reputational damage associated with resolving customer product and warranty and indemnification claims; and other events and trends on a national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. Our Report on Form 10-Q filed on March 13, 2014, LSI’s Report on Form 10-Q filed on May 1, 2014 and Report on Form 10-K filed on February 26, 2014 and our other filings with the Securities and Exchange Commission, or “SEC” (which you may obtain for free at the SEC’s website at http://www.sec.gov) discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no intent or obligation to publicly update or revise any of these forward looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Avago Contacts
         Bin Jiang
         Investor Relations
         +1 408 435 7400
         investor.relations@avagotech.com

         LSI Contacts
         David Miller
         Media Relations
         +1 408 712 7813
         Dave.c.miller@lsi.com

(GLOW) to Present at the 15th Annual B. Riley & Co. Annual Investor Conference

DENVER, May 6, 2014  — Glowpoint, Inc. (NYSE MKT:GLOW), a leading provider of video collaboration services and network solutions, will present at the 15^th Annual B. Riley & Co. Annual Investor Conference, Monday, May 19, 2014 at Loews Santa Monica Beach Hotel.

Management will provide a company overview and update at 11:30 a.m. PT on Monday, May 19^th. The presentation will be available on the company website and broadcast live via webcast. Participants may access the webcast link at http://glowpoint.com/investor-relations.

About Glowpoint

Glowpoint, Inc. (NYSE MKT:GLOW) provides video collaboration, network, and support services to large enterprises and mid-sized companies to support their unified communications (UC) strategies and business goals. More than 1,000 organizations in 96 countries rely on our unmatched experience, business-class support and cloud-based services to collaborate with colleagues, business partners, and customers more effectively. To learn more please visit www.glowpoint.com.

(RDNT) to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

LOS ANGELES, May 6, 2014  — RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Thursday, May 15, 2014 at 10:40 a.m. Pacific Time.

There will be simultaneous and archived webcasts available at http://www.veracast.com/webcasts/baml/healthcare2014/id75305321466.cfm and www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website.

About RadNet, Inc.

RadNet, Inc. is a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 250 fully-owned and operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, Rhode Island, New Jersey and New York. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 6,000 employees. For more information, visit http://www.radnet.com.

CONTACT: RadNet, Inc.
         Mark Stolper, Executive Vice President and
         Chief Financial Officer
         310-445-2800

(STXS) to Present New Clinical Evidence, Features of Automated Technologies

ST. LOUIS, May 6, 2014  — Stereotaxis, Inc. (Nasdaq:STXS) today announced several firsts for its eleventh appearance at the annual Heart Rhythm Society (HRS) Scientific Sessions, to be held May 7-10, 2014 in San Francisco, CA. With a central theme of “Efficiency Established; Outcomes Proven; Safety Undoubted,” the Company will share new clinical evidence around efficiencies achieved through its Epoch™ Solution, showcase a seminal feature of its latest generation user interface and, for the first time, present the value of its Vdrive™ Robotic Navigation System to a U.S. audience.

“The electrophysiology (EP) community has long recognized Stereotaxis as world-class in safety and efficacy,” said William C. Mills, Stereotaxis Chief Executive Officer. “Through an internal study, we now have evidence of significant improvement in procedure efficiency (as measured by achievable total procedure time and ablation time) and an accelerated learning curve using the Niobe® ES Magnetic Navigation System. Until now, the claim that a proficient Niobe user can often perform faster ablation procedures compared to alternative EP treatments has been largely anecdotal. This information provides a baseline for substantiation of improved efficiency as we continue to deliver advances in robotic EP ablation.”

Among the innovations Stereotaxis is launching at HRS is a key feature of the Company’s enhanced user interface for the Epoch platform. As its name indicates, Ablation History provides a history of the catheter’s power output and duration of energy application at each location during the ablation through an intuitive graphical display. With this feature, physicians can retrace their ablation-related activity and potentially identify gaps in lesion lines on a real-time basis. The Company believes this additional capability will assist physicians in visualizing the applied treatment, reducing the need for touch-up at the end of the procedure and minimizing unnecessary tissue injury, which should lead to improved procedure efficiency and outcomes. Physicians will have the opportunity to see the feature in a live simulation lab at the Stereotaxis booth.

Ablation History is the latest capability offered through a platform that has been utilized in approximately 70,000 robotic EP procedures to date. More than 500 EP physicians worldwide currently rely on Stereotaxis technology, which includes the Niobe system, Vdrive system and accessory disposables, and the Odyssey® Information Management Solution. The Vdrive robotic navigation system is a relatively new offering in the U.S., receiving FDA clearance of its V-Sono™ ICE Catheter Manipulator in July 2013. Now installed in nine U.S. sites, the system has aided in more than 100 Niobe procedures. In addition, the V-Loop™ Variable Loop Catheter Manipulator has been submitted for FDA clearance. This year represents the first opportunity the Company will have to formally present the features and benefits of the Vdrive system to HRS participants.

During a breakfast symposium held at the HRS Rhythm Theatre on May 8 at 6:30 a.m. and moderated by Stereotaxis Chief Medical Officer Dr. Gery Tomassoni, two renowned EP physicians and researchers, Dr. Hiroshi Nakagawa (University of Oklahoma Health Sciences Center) and Dr. Eugene Crystal (Sunnybrook Health Sciences Centre, Toronto), will speak to the unique clinical value and procedure efficiency achieved with Stereotaxis solutions.

In addition, the following physicians will be on hand at the Stereotaxis booth (Booth 2002) to engage with participants on building a successful Stereotaxis program:

• Erik Wissner, M.D., Ph.D., Asklepios Klinik St. Georg (Hamburg, Germany) – May 8, 9:30 a.m.
• J. David Burkhardt, M.D., Texas Cardiac Arrhythmia Institute (Austin, TX) – May 8, 10:00 a.m.
• Sabine Ernst, M.D., Ph.D., Royal Brompton Hospital (London, England) – May 9, 10:00 a.m.
• Aseem Desai, M.D., Mission Hospital (Mission Viejo, CA) – May 9, 11:00 a.m.

Furthermore, HRS scientific proceedings will feature a series of abstracts and posters with the latest clinical data related to Stereotaxis technologies, including:

• “Catheter Ablation of Ischemic Ventricular Tachycardia with Remote Magnetic Navigation STOP VT Trial (Study to Obliterate Persistent Ventricular Tachycardia);” Jan Skoda, et al.
• “Creation of Complete Conduction Block Across the Mitral Isthmus Using Magnetic Catheter Maneuvering System: Importance of Magnetic Field Direction for Ablation Within the Coronary Sinus;” Hiroshi Nakagawa, et al.
• “The Impact of Pulmonary Vein Diameter on Freedom from Atrial Fibrillation Using Remote Magnetic Navigation for Circumferential Pulmonary Vein Isolation;” Leonard Bergau, et al.
• “Remote Magnetic Navigation versus Manual Navigation for Irrigated Point-by-Point Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: Comparative 3-Year Data;” Frederick T. Han, et al.
• “Maintenance of Sinus Rhythm Following Ablation of Persistent and Long-Standing Persistent Atrial Fibrillation: An Achievable Goal!;”Harish Manyam, et al.
• “Successful Ablation of PVCs Emanating from an Immediate Parahisian Location using Remote Magnetic Navigation and an Open Irrigated Catheter;”Jose Cuellar, et al.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis’ core Epoch™ Solution includes the Niobe® ES Remote Magnetic Navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan and elsewhere. The V-Sono™ ICE catheter manipulator has received U.S. clearance, and the V-Loop™ variable loop catheter manipulator has been submitted for review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, the outcome of various shareholder litigation filed against Stereotaxis, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         314-678-6155

         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300
         stxs@mkr-group.com

(RWC) Wireless Receives $1.4 Million Order From Federal Law Enforcement Agency

WEST MELBOURNE, Fla., May 6, 2014  — RELM Wireless Corporation (NYSE MKT: RWC) today announced an order totaling approximately $1.4 million from a law enforcement agency of the federal government. The orders are primarily for RELM’s KNG-Series Digital P-25 VHF mobile and portable radios with trunking. The order is expected to be fulfilled during the second quarter of 2014.

RELM President and Chief Executive Officer David Storey commented, “We are very excited about this order.  It represents a material investment by a respected federal law enforcement agency that is a first-time RELM customer. This is a high-profile opportunity to further validate our outstanding reputation in public safety applications, and demonstrate RELM’s exceptional capabilities, quality and customer service. Our goal is to exceed the customer’s expectations, laying the foundation and confidence for more business in the future with this and other federal, state and municipal law enforcement customers.”

About APCO Project 25 (P25)

APCO Project 25 (P25), which requires interoperability among compliant equipment regardless of the manufacturer, was established by the Association of Public-Safety Communications Officials and is approved by the U.S. Department of Homeland Security. The shift toward interoperability gained momentum as a result of significant communications failures in critical emergency situations. RELM was one of the first manufacturers to develop P25-compliant technology.

About RELM Wireless Corporation

As an American Manufacturer for more than 65 years, RELM Wireless Corporation has produced high‑specification two‑way communications equipment of unsurpassed reliability and value for use by public safety professionals and government agencies, as well as radios for use in a wide range of commercial and industrial applications. Advances include a broad new line of leading digital two‑way radios compliant with APCO Project 25 specifications. RELM’s products are manufactured and distributed worldwide under BK Radio and RELM brand names. The Company maintains its headquarters in West Melbourne, Florida and can be contacted through its web site at www.relm.com or directly at 1‑800‑821‑2900. The Company’s common stock trades on the NYSE MKT market under the symbol “RWC”.

This press release contains certain forward-looking statements that are made pursuant to the “Safe Harbor” provisions of the Private Securities Litigation Reform Act Of 1995. These forward-looking statements concern the Company’s operations, economic performance and financial condition and are based largely on the Company’s beliefs and expectations. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others, the following: changes or advances in technology; the success of our LMR product line; competition in the land mobile radio industry; general economic and business conditions, including federal, state and local government budget deficits and spending limitations; the availability, terms and deployment of capital; reliance on contract manufacturers and suppliers; heavy reliance on sales to agencies of the U.S. government; our ability to utilize deferred tax assets; retention of executive officers and key personnel; our ability to manage our growth; government regulation; business with manufacturers located in other countries; our inventory and debt levels; protection of our intellectual property rights; acts of war or terrorism; any infringement claims; provisions in our charter documents and under Nevada law that may discourage a potential takeover; maintenance of our NYSE MKT listing; and the effect on our stock price and ability to raise equity capital of future sales of shares of our common stock. Certain of these factors and risks, as well as other risks and uncertainties, are stated in more detail in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in the Company’s subsequent filings with the SEC. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.

(PSMI) Ships First UltraCMOS® 10 Production Units

Peregrine Semiconductor Corp. (NASDAQ: PSMI), founder of RF SOI (silicon on insulator) and pioneer of advanced RF solutions, announces shipment of the first RF switches built on the UltraCMOS 10 technology platform. With partner GLOBALFOUNDRIES, the company also announces the completion of product and process qualification for the advanced RF SOI technology.

Introduced in October 2013, UltraCMOS 10 technology provides smartphone manufacturers with unparalleled performance and flexibility. The 130 nm technology combines the performance of UltraCMOS technology with the economies of SOI, and it delivers a more than 50-percent performance improvement over comparable solutions. The advanced technology addresses the unique growth requirements for mobile applications and is the foundation for Peregrine’s next-generation RF switches, tuners and power amplifiers, including the industry’s first reconfigurable RF front end, UltraCMOS Global 1.

“UltraCMOS 10 technology builds on Peregrine’s 25 year legacy of providing high-performance, integrated RF solutions,” says Mark Miscione, vice president of RF technology solutions at Peregrine Semiconductor. “Our technology platform was created to advance the future of RF design with a comprehensive SOI solution. Peregrine is pleased to ship the first of our UltraCMOS 10 switches.”

To develop UltraCMOS 10 technology, Peregrine collaborated with GLOBALFOUNDRIES, a tier-one foundry and leading provider of semiconductor manufacturing technology. Together, the companies co-developed a unique fabrication flow for the versatile RF SOI platform. With the qualification process complete, UltraCMOS 10 technology is now a fully qualified technology platform.

“Peregrine Semiconductor has proven to be an excellent partner for GLOBALFOUNDRIES,” says KC Ang, senior vice president and general manager of Singapore operations at GLOBALFOUNDRIES. “Peregrine has a strong history of innovation and performance leadership, and we believe this trend will continue with the co-developed UltraCMOS 10 technology, the highest performance RF SOI technology in existence.”

USE OF FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements regarding our management’s future expectations, beliefs, intentions, goals, strategies, plans and prospects. Such statements constitute “forward-looking” statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The achievement of the matters covered by such forward-looking statements involves risks, uncertainties and assumptions. If any of these risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results, performance or achievements could be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to, our dependence on a limited number of customers for a substantial portion of our revenues; intellectual property risks; intense competition in our industry; our ability to develop and introduce new and enhanced products on a timely basis and achieve market acceptance of those products; consumer acceptance of our customers’ products that incorporate our solutions; our lack of long-term supply contracts and dependence on limited sources of supply; and potential decreases in average selling prices for our products.

For further information regarding risks and uncertainties associated with Peregrine’s business, please refer to the filings that we make with the Securities and Exchange Commission from time to time, including those set forth in the section entitled “Risk Factors” in our Form 10-K for the year ended December 29, 2012 and additional information that will be set forth in our Form 10-K that will be filed for the year ended December 28, 2013, which should be read in conjunction with these financial results. These documents are available on the SEC Filings section of the Investor Relations section of our website at http://investors.psemi.com/. Please also note that forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information, becomes available in the future.

ABOUT PEREGRINE SEMICONDUCTOR

Peregrine Semiconductor (NASDAQ: PSMI), founder of RF SOI (silicon on insulator), is a leading fabless provider of high-performance, integrated RF solutions. Since 1988 Peregrine and its founding team have been perfecting UltraCMOS® technology – a patented, advanced form of SOI – to deliver the performance edge needed to solve the RF market’s biggest challenges, such as linearity. With products that deliver best-in-class performance and monolithic integration, Peregrine is the trusted choice for market leaders in automotive, broadband, industrial, Internet of Things, military, mobile devices, smartphones, space, test-and-measurement equipment and wireless infrastructure. Peregrine holds more than 180 filed and pending patents and has shipped more than 2 billion UltraCMOS units. For more information, visit http://www.psemi.com.

The Peregrine Semiconductor name, logo, and UltraCMOS are registered trademarks of Peregrine Semiconductor Corporation in the U.S.A., and other countries. All other trademarks mentioned herein are the property of their respective owners.

(BTX) Raises $6.4 Million in Equity Financing

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately $6.4 million in equity financing. The funds were raised from current long-term investors in the Company and will be used for funding product development, including this year’s anticipated pivotal Renevia™ clinical trial, as well as other general operating expenses.

About BioTime

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime’s therapeutic and research products include a wide array of proprietary PureStem^® progenitors, HyStem^® hydrogels, culture media, and differentiation kits. BioTime is developing Renevia™ (a HyStem^® product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend^®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend^® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

• Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine.

• OncoCyte Corporation is developing products and technologies to diagnose and treat cancer.

• Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.

• LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and distributes GeneCards^®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery^® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.

• ES Cell International Pte Ltd., a Singapore private limited company, developed clinical and research grade hES cell lines and plans to market those cell lines and other BioTime research products in over-seas markets as part of BioTime’s ESI BIO Division.

• BioTime Asia, Limited, a Hong Kong company, may offer and sell products for research use for BioTime’s ESI BIO Division.

• OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries.

• ReCyte Therapeutics, Inc. is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.

Additional information about BioTime can be found on the web at www.biotimeinc.com.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com

(OMEX) Gold Recovered During First Reconnaissance Dive

Expedition to Conduct Pre-Disturbance Survey, Archaeological Excavation, Scientific Experiments and Recover Remaining Gold Now Underway

TAMPA, Fla., May 5, 2014  — Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), a pioneer in the field of deep-ocean exploration, recovered nearly 1,000 ounces of gold during the first reconnaissance dive to the SS Central America shipwreck site on April 15,2014.

Recovered gold included five gold ingots and two $20 Double Eagle coins (one 1857 minted in San Francisco and one 1850 minted in Philadelphia). The gold ingots were stamped with assayer’s marks and weights that range from 96.5 to 313.5 troy ounces.

The two-hour reconnaissance dive was conducted during the transit of Odyssey’s research vessel, the Odyssey Explorer, from the United Kingdom to Charleston, South Carolina, to mobilize for the project, which is being conducted under contract with the receiver of Recovery Limited Partnership (RLP). RLP director of operations Craig Mullen and RLP chief scientist/historian Bob Evans accompanied the Odyssey team for the dive operation. Mr. Evans previously served as chief scientist, historian and later as curator for the initial Central America recovery operations conducted between 1988 and 1991.

During the dive, Odyssey’s ROV ZEUS flew over the shipwreck to assess the current condition of the site. Gold ingots and other artifacts were clearly visible on the surface of the site during the dive and no excavation was required for their removal. Given the reconnaissance purpose of the dive, only five gold ingots, two gold coins, a bottle, a piece of pottery, a sample of the shipwreck’s wooden structure, and an element of a scientific experiment that was left at the site more than 20 years ago were recovered. The positions of the recovered artifacts were documented for archaeological purposes and will be noted in the detailed site plan that is being created. The archaeological excavation of the site will be undertaken once the pre-disturbance survey provides detailed documentation of the site.

“This dive confirms for me that the site has not been disturbed since 1991, when I was last there,” said Bob Evans chief scientist/historian for RLP.

RLP director of operations Craig Mullen added, “The skill exhibited and results achieved during the initial reconnaissance dive reinforces our belief that the Odyssey team was the absolute best choice for this project. In addition to the cargo recovery operation, we plan to collect deep-ocean biological samples for Dr. Timothy Shank, a deep-ocean biologist and head of the Molecular Ecology and Evolution Laboratory at Woods Hole Oceanographic Institution. Our objective is to document and provide Dr. Shank with samples of species that have returned to the site since previous operations ended. Odyssey’s documentation capabilities will contribute significantly to scientific understanding of deep-ocean biological processes. This continues a history of supporting scientific research at the site.”

Odyssey was selected for the project by Ira Owen Kane, the court-appointed receiver who represents Recovery Limited Partnership (RLP) and Columbus Exploration LLC (CE). The contract has been approved by the Common Pleas Court of Franklin County, Ohio, which has given Mr. Kane responsibility with overseeing the recovery project.

The archaeological excavation, valuable cargo recovery and ship-board conservation will be conducted and underwritten by Odyssey on behalf of RLP. In return, Odyssey will receive 80% of recovery proceeds until a fixed mobilization fee and a negotiated day rate are paid. Thereafter, Odyssey will receive 45% of the recovery proceeds.

About the SS Central America

The SS Central America was an 85-meter (280-foot) wooden-hulled, copper-sheathed, three-masted side-wheel steamship launched in 1853 as the SS George Law. Operating during the California Gold Rush era, the ship was in continuous service on the Atlantic leg of the Panama Route between New York and San Francisco, making 43 round trips between New York and Panama. The Central America was caught in a hurricane and sank 160 miles off the coast of South Carolina on September 12, 1857. When she was lost, the SS Central America was carrying a large consignment of gold for commercial parties, mainly in the form of ingots and freshly minted U.S. $20 Double Eagle coins. Because of the large quantity of gold lost with the ship, public confidence in the economy was shaken, which contributed to the Panic of 1857.

The Columbus-America Discovery Group, acting as agent for RLP, confirmed the location of the Central America shipwreck site in September 1988 at a depth of 2,200 meters (7,200 feet). Recovery operations were conducted over a four-year period (1988-1991) and a large quantity of commercial gold was recovered from approximately 5% of the shipwreck site during more than 1,000 hours of bottom time.

Odyssey Marine Exploration has been awarded the exclusive contract to conduct an archaeological excavation and recover the remaining valuable cargo from the SS Central America shipwreck.

About RLP

Recovery Limited Partnership (RLP) was organized in 1985 as an Ohio limited partnership to finance the SS Central America project. Columbus-American Discovery Group LLC (CADG), as agent for RLP, initiated an admiralty action in the United States District Court of the Eastern District of Virginia to establish ownership of the shipwreck and all of its contents. After more than a decade of litigation, the court ruled that CADG owned 92.5% of the recovered gold.

Ira Owen Kane was appointed as the receiver for Recovery Limited Partnership and Columbus Exploration LLC by the Common Pleas Court of Franklin County, Ohio. At the direction of the court, the goal of the receiver is to preserve and operate the business of RLP and Columbus Exploration for the benefit of the investors and their creditors, and to do so by initiating the operations necessary to recover valuable cargo and cultural heritage items that remain on the SS Central America shipwreck site.

About Odyssey Marine Exploration

Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in deep-ocean exploration using innovative methods and state of-the-art technology for shipwreck projects and mineral exploration. For additional details, please visit www.odysseymarine.com. The company also maintains a Facebook page at http://www.facebook.com/OdysseyMarine and a Twitter feed @OdysseyMarine. For additional details on Odyssey Marine Exploration, please visit www.odysseymarine.com.

Forward Looking Information

Odyssey Marine Exploration believes the information set forth in this Press Release may include “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the Securities and Exchange Commission on March 17, 2014. The financial and operating projections as well as estimates of mining assets are based solely on the assumptions developed by Odyssey that it believes are reasonable based upon information available to Odyssey as of the date of this release. All projections and estimates are subject to material uncertainties, and should not be viewed as a prediction or an assurance of actual future performance. The validity and accuracy of Odyssey’s projections will depend upon unpredictable future events, many of which are beyond Odyssey’s control and, accordingly, no assurance can be given that Odyssey’s assumptions will prove true or that its projected results will be achieved.

CONTACT: MEDIA CONTACT:
         Liz Shows
         Odyssey Marine Exploration, Inc.
         (813) 876-1776 x 2335
         lshows@odysseymarine.com

         INVESTOR RELATIONS CONTACT:
         Ron Both
         Liolios Group, Inc.
         (949) 574-3860
         OMEX@liolios.com

(PSDV) Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida’s Tethadur™ technology to provide sustained release of Avastin at the 14^th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).

pSivida’s Dinesh K. Nadarassan presented a poster entitled “Sustained Release of Bevacizumab (Avastin) from BioSilicon”. The data from preclinical studies conducted by pSivida concluded that long-term sustained release of antibodies such as Avastin is achievable with Tethadur, a form of pSivida’s BioSilicon™ technology, and that the release of the antibodies is controllable over a wide range by adjusting the pore size and surface area of Tethadur.

“The implications of the ability to control the duration of sustained delivery of antibodies through pore size are significant,” said Dr. Paul Ashton, president and chief executive officer of pSivida. “By varying pore size, we believe the release rate of antibodies loaded into Tethadur can be controlled, which could permit sustained delivery of antibodies that currently must be delivered by frequent injections. For example, Avastin and the two of the top-selling Veg-F ophthalmic drugs today are injected as frequently as once a month.”

pSivida’s Tethadur, an application of BioSilicon technology, is designed to provide sustained delivery of large biologic molecules, including peptides, proteins and antibodies. BioSilicon technology utilizes a fully-erodible, honeycomb structure of nano-porous, elemental silicon to provide sustained delivery of therapeutics. The study evaluated the effect of pore size in Tethadur on Avastin release over a period of three weeks.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technologies, Durasert™ and Tethadur™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., is marketed in the U.K. and Germany and has also received marketing authorization in Austria, France, Portugal, and Spain and is awaiting authorization in Italy. Alimera has filed for ten additional EU country approvals through the Mutual Recognition Procedure. Alimera is seeking FDA approval for ILUVIEN for DME in the US. pSivida has commenced a Phase III clinical trial of Medidur™ for the treatment of posterior uveitis, a chronic back-of-the-eye disease, which uses the same micro-insert as ILUVIEN. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida’s FDA-approved Retisert®, licensed to Bausch & Lomb Incorporated, provides long-term, sustained drug delivery to treat posterior uveitis.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: ability of BioSilicon and Tethadur to successfully deliver proteins, peptides and other large biologic molecules on a sustained basis; Alimera’s ability to obtain regulatory approval for, and if approved, to finance, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the U.S.; Alimera’s ability to finance, achieve additional marketing approvals, obtain adequate pricing and reimbursement for, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the EU; the ability to finance, complete and achieve a successful outcome for Phase III trials for, and file and achieve marketing approvals for, Medidur for posterior uveitis, including achieving acceptable risk-to-benefit and safety profiles in light of the CRL for ILUVIEN; initiation, financing and success of Latanoprost Product Phase II trials and any exercise by Pfizer of its option; ability to develop product candidates and products and potential related collaborations; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; continued sales of Retisert; adverse side effects; ability to attain profitability; ability to obtain additional capital; further impairment of intangible assets; fluctuations in operating results; decline in royalty income; ability to, and to find partners to, develop and market products; termination of license agreements; competition and other developments affecting sales of products; market acceptance; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp

Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562

LinkedIn: http://www.linkedin.com/company/psivida

Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts

The President’s Blog: http://www.thechairmansblog.com/paul-ashton

For more information on pSivida, visit www.psivida.com.

(LPTH) to Present at the 15th Annual B. Riley & Co. Investor Conference

(ARTX) Battery & Power Systems Division Receives Orders In Excess Of $5 Million

ANN ARBOR, Mich., May 5, 2014  — Arotech Corporation (Nasdaq GM: ARTX), a provider of quality defense and security products for the military, law enforcement and homeland security markets, announced that it has received new orders from military customers amounting to $5.2 million. These orders will be delivered to customers during the remainder of 2014.

Robert S. Ehrlich, Arotech’s Chairman and Chief Executive Officer commented, “Our battery division is having a very exciting year so far. We have seen important R&D developments such as our progress with the iron flow battery, the highly accretive acquisition of UEC, as well as continued order momentum. Some of these recent orders were from leading global defense manufacturers that continue to purchase from us, demonstrating their trust in the reliability and quality of our products for use in a rugged military environment.”

Continued Mr. Ehrlich, “In only a few weeks since the close of the acquisition, UEC has already proven itself as a highly complementary business to our Battery and Power Systems Division. Our combination has already opened up new market opportunities for us and we are realizing some strong synergies particularly in our sales and marketing efforts. As we continue our work in assimilating UEC into Arotech, I am becoming ever more excited with regard to the growth potential within our battery division over the coming years.”

About Arotech Corporation

Arotech Corporation is a leading provider of quality defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates through two major business divisions: Training and Simulation, and Battery and Power Systems.

Arotech is incorporated in Delaware, with corporate offices in Ann Arbor, Michigan and research, development and production subsidiaries in Alabama, Michigan, South Carolina and Israel.

Investor Relations Contact

For more information, please contact: Ehud Helft and Kenny Green at GK Investor Relations, Tel: 1 646 201 9246. E-mail: arotech@gkir.com

Except for the historical information herein, the matters discussed in this news release include forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, readers are cautioned not to place undue reliance on these forward-looking statements, as they are subject to various risks and uncertainties that may cause actual results to vary materially. These risks and uncertainties include, but are not limited to, risks relating to: product and technology development; the uncertainty of the market for Arotech’s products; changing economic conditions; delay, cancellation or non-renewal, in whole or in part, of contracts or of purchase orders (including as a result of budgetary cuts resulting from automatic sequestration under the Budget Control Act of 2011); and other risk factors detailed in Arotech’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in Exhibit 99.3 to Arotech’s Current Report on 8-K, filed on April 1, 2014, and other filings with the Securities and Exchange Commission. Arotech assumes no obligation to update the information in this release. Reference to the Company’s website above does not constitute incorporation of any of the information thereon into this press release.

(MITK) Enables Members 1st Federal Credit Union to Acquire New Credit Card Members, Balances

SAN DIEGO and MECHANICSBURG, Pa., May 5, 2014  — Mitek (Nasdaq:MITK) (www.miteksystems.com), the leading innovator of mobile imaging for financial transactions, today announced that Members 1st Federal Credit Union will use Mobile Photo Balance Transfer™ to acquire new credit card members and balances. Mitek’s Mobile Photo Balance Transfer™ solution is the mobile equivalent of traditional balance transfer marketing programs and appeals to the highly desirable “mobile only” and “mobile first” consumers. Members 1st Federal Credit Union is the first credit union in the Mid-Atlantic to offer this service to their members.

In a matter of minutes, Members 1st members will be able to accept a low interest balance transfer offer from their mobile banking app and then transfer balances from another credit issuer to a new Members 1st credit card account. This is accomplished by using a smartphone camera to snap a photo of their credit card bill coupon. The information captured will be used to transfer the remaining balance to their new Members 1st credit card account. This solution gives members a quick, simple way to lower their interest rates without cumbersome data entry on a mobile device.

“Mobile Photo Balance Transfer™ takes the hassle out of manually entering account information on small smartphone keyboards,” James B. DeBello, president and CEO at Mitek said. “Our solution uses the power of mobile imaging to support Members 1st marketing programs designed for new credit card customer acquisition using a mobile device.”

About Members 1st Federal Credit Union

Members 1st is a member-owned full service financial institution located in South Central Pennsylvania. In business since 1950, Members 1st now serves over 250,000 members with 50 plus full-service branches including 7 in-school branches. Their extensive branch network and electronic delivery channels allows the membership to be engaged in their financial future through whatever means they are most comfortable with.

Follow us on Twitter: @members1stfcu

Follow us on FaceBook: www.facebook.com/members1stfederalcreditunion

Read our latest blog post: http://members1stblog.org

About Mitek                                                                                                 

Headquartered in San Diego, CA, Mitek (Nasdaq:MITK) is the leading innovator of mobile imaging for financial transactions. Mitek’s patented mobile photo technology automatically captures images of personal and financial documents and then extracts relevant data. This enables consumers to use the Camera as a Keyboard™ to reduce friction for mobile check deposit, account opening, bill payment, insurance quoting, and many other use cases. This innovative technology is licensed by more than 1,700 organizations and used by tens of millions of consumers enabling increased customer acquisition, retention and operational efficiency. www.miteksystems.com

Follow Us on LinkedIn: http://www.linkedin.com/company/mitek-systems-inc.

Follow Us on Twitter: @miteksystems

See us on YouTube: http://www.youtube.com/miteksystems

Read our latest blog post: http://www.miteksystems.com/blog

CONTACT: Mitek Contacts

         Ann Reichert
         Director of Marketing
         pr@miteksystems.com

         Katherine Verducci
         MIX Public Relations
         pr@mix-pr.com

(BAGL) Announces $20 Million Share Repurchase Program

Einstein Noah Restaurant Group, Inc. (NASDAQ:BAGL), a leader in the quick-casual segment of the restaurant industry operating under the Einstein Bros.® Bagels, Noah’s New York Bagels®, and Manhattan Bagel® brands, today announced that its Board of Directors has authorized a $20 million share repurchase program. The Company expects to initiate repurchases promptly for up to $5 million of its common stock in the open market or through privately negotiated transactions.

The authorization does not obligate the Company to repurchase any particular amount of common stock and it may be suspended or discontinued at any time. The amount and timing of any purchases under the program will depend upon a number of factors, including the price and availability of the Company’s shares, trading volume, and general market conditions. Purchases under the repurchase program will comply with applicable Securities and Exchange Commission rules.

About Einstein Noah Restaurant Group

Einstein Noah Restaurant Group, Inc. is a leading company in the quick-casual segment of the restaurant industry that operates, franchises and licenses locations under the Einstein Bros.®, Noah’s New York Bagels® and Manhattan Bagel® brands. The Company’s retail system consists of over 860 restaurants in 42 states and the District of Columbia. It also operates a dough production facility. The Company’s stock is traded on the NASDAQ under the symbol BAGL. Visit www.einsteinnoah.com for additional information.

Forward Looking Statement Disclosure

Certain statements in this press release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating), or achievements to differ materially from the future results, performance (financial or operating), or achievements expressed or implied by such forward-looking statements. These and other risks are more fully discussed in the Company’s SEC filings, including, but not limited to, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Any forward-looking statements by the Company, are intended to speak only as of the date such statements are made. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the Securities and Exchange Commission, the Company does not undertake to publicly update any forward-looking statements in this news release or with respect to matters described herein, whether as a result of any new information, future events or otherwise.

(PCYG) to Present at the 15th Annual B. Riley & Co. Investor Conference

SALT LAKE CITY, May 2, 2014  — Park City Group (Nasdaq:PCYG), a cloud-based software company that uses big data management to help retailers and their suppliers sell more, stock less and see everything, today announced that Randy Fields, Chairman and CEO, will present at the 15^th Annual B. Riley & Co. Investor Conference on Monday, May 19, 2014. The conference is being held at the Loews Santa Monica Beach Hotel in Santa Monica, California. Park City Group’s presentation is scheduled to begin at 10:00 a.m. local time. A live and archived webcast of the presentation may be accessed at the Company’s website, www.parkcitygroup.com.

About Park City Group

Park City Group (Nasdaq:PCYG) is a Software-as-a-Service (“SaaS”) provider that brings unique visibility to the consumer goods supply chain, delivering actionable information that ensures product is on the shelf when the consumer expects it as well as providing food safety tracking information. The Company’s service increases customers’ sales and profitability while enabling lower inventory levels and ensuring regulatory compliance for both retailers and their suppliers. Through a process known as Consumer Driven Sales Optimization™, Park City Group helps its customers turn information into cash and increased sales, using the largest scan based platform in the world. Scan based trading provides retail trading partners with a distinct competitive advantage through scan sales that provides store level visibility and sets the supply chain in motion. And since it is scan based, it can be used in a Direct Store Delivery (DSD) or warehouse setting.

CONTACT: Investor Relations Contact:

         Dave Mossberg
         Three Part Advisors, LLC
         817-310-0051

         Jeff Elliott
         Three Part Advisors, LLC
         972-423-7070

(SVVC) Value Fund Settles Proxy Contest With Bulldog Investors

SAN JOSE, Calif., May 2, 2014  — Firsthand Technology Value Fund, Inc. (Nasdaq:SVVC) (the “Fund”), a publicly-traded venture capital fund that invests in technology and cleantech companies, announced today that it has entered into an agreement with Bulldog Investors, LLC (“Bulldog”), the Fund’s largest shareholder group.

Under the terms of the settlement, Bulldog has agreed to (1) withdraw its two nominees for the Fund’s Board of Directors, (2) withdraw its proposals regarding (i) termination of the Fund’s Investment Management Agreement and (ii) consideration by the Board of a share repurchase program, (3) not present any proposals at the Annual Meeting, and (4) vote its shares in accordance with the Board’s recommendations.

The settlement also provides that the Fund’s Board approve a plan for the Fund to repurchase up to $10 million of common stock in open market purchases during 2014, and to conduct a self-tender offer for at least $20 million worth of common stock at 95% of net asset value to be completed no later than January 31, 2015. Further, the Fund has agreed to liquidate its Facebook and Twitter holdings no later than September 30, 2014 and October 31, 2014, respectively, and to distribute any net realized gains from those holdings to shareholders within 60 days of completing those liquidations.

The Fund intends to deliver updated proxy materials and voting instructions to shareholders. Shareholders needing any assistance voting their shares should call 1.800.733.6198.

About Firsthand Technology Value Fund

Firsthand Technology Value Fund, Inc. is a publicly-traded venture capital fund that invests in technology and cleantech companies. More information about the Fund and its holdings can be found online at www.firsthandtvf.com.

The Fund is a non-diversified, closed-end investment company that elected to be treated as a business development company under the Investment Company Act of 1940. The Fund’s investment objective is to seek long-term growth of capital. Under normal circumstances, the Fund will invest at least 80% of its total assets for investment purposes in technology and cleantech companies.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined under the U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to materially differ from the Fund’s historical experience and its present expectations or projections indicated in any forward-looking statement. These risks include, but are not limited to, changes in economic and political conditions, regulatory and legal changes, technology and cleantech industry risk, valuation risk, non-diversification risk, interest rate risk, tax risk, and other risks discussed in the Fund’s filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Fund undertakes no obligation to publicly update or revise any forward-looking statements made herein. There is no assurance that the Fund’s investment objectives will be attained. We acknowledge that, notwithstanding the foregoing, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 does not apply to investment companies such as us.

CONTACT: Heather Hohlowski
         Firsthand Capital Management, Inc.
         (408) 624-9525
         vc@firsthandtvf.com

(MCHX) to Present at the Jefferies 2014 Global Conference

Marchex, Inc. (NASDAQ:MCHX) today announced that Michael Arends, Chief Financial Officer, will present at the following investor conference:

Jefferies 2014 Global Technology, Media & Telecommunications Conference
Date: Tuesday, May 6^th
Time: 2:30pm Eastern Time
Location: Epic Hotel, Miami, FL

The live audio webcast of the Marchex presentation will be available by visiting Events in the Investor Relations section of the Marchex website (http://www.marchex.com/investors/events.html). An archived version of the webcast will be available four hours after the completion of the presentation.

About Marchex

Marchex is a mobile advertising technology company. The company provides a suite of products and services for businesses that depend on consumer phone calls to drive sales. Marchex’s mobile advertising platform delivers new customer phone calls to businesses, while its technology analyzes the data in these calls to help maximize ad campaign results. Marchex disrupts traditional advertising models by giving businesses full transparency into their ad campaign performance and charging them based on new customer acquisition.

Please visit www.marchex.com, blog.marchex.com or @marchex on Twitter (Twitter.com/Marchex), where Marchex discloses material information from time to time about the company, its financial information, and its business.

(CDZI) Announces Ruling In California Environmental Quality Act Litigation

Court Upholds Environmental Impact Report Supporting Project Approvals

Today, Cadiz Inc. (NASDAQ:CDZI) (“Cadiz”, the “Company”) announced the issuance of the trial court decision to uphold the environmental approvals of the Cadiz Valley Water Conservation, Recovery and Storage Project (“Cadiz Project”). The Orange County Superior Court ruling denied all 6 petitions challenging the Project’s environmental review and upheld the actions of the Santa Margarita Water District and the County of San Bernardino in approving the Project, the environmental impact report and groundwater management plan. The ruling comes after exhaustive briefing and lengthy hearings that spanned over 3 months.

“Cadiz is grateful for the thorough and deliberate review by the trial court and the Court’s validation of the environmental review conducted for the Water Project,” said Cadiz CEO Scott Slater. “We will provide further updates shortly.”

About Cadiz

Founded in 1983, Cadiz Inc. is a publicly-held renewable resources company that owns 70 square miles of property with significant water resources in Southern California. The Company is engaged in a combination of organic farming and water supply and storage projects at its properties and abides by a wide-ranging “Green Compact” focused on environmental conservation and sustainable practices to manage its land, water and agricultural resources. For more information about Cadiz, visit http://www.cadizinc.com/.

FORWARD LOOKING STATEMENT: This release contains forward-looking statements that are subject to significant risks and uncertainties, including statements related to the future operating and financial performance of the Company and the financing activities of the Company. Although the Company believes that the expectations reflected in our forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected in the Company’s forward-looking statements include the Company’s ability to maximize value for Cadiz land and water resources, the Company’s ability to obtain new financing as needed, the receipt of additional permits for the water project and other factors and considerations detailed in the Company’s Securities and Exchange Commission filings.

(JIVE) & Cisco, Complete And Fully Integrated Communication And Collaboration Solution

New Offer Provides Cisco Customers Worldwide Seamless Experience with Jive’s Market-leading Enterprise Collaboration and Community Solution

PALO ALTO, Calif., May 1, 2014  — Jive Software, Inc. (Nasdaq: JIVE), the world’s premier provider of communications and collaboration solutions, today announced a relationship with Cisco to offer businesses a better way to work together to drive greater productivity, collaboration, ideation and customer service. By combining Jive’s industry-leading enterprise collaboration platform with Cisco’s real-time technologies like WebEx and Jabber, the result is a complete communication and collaboration offering making it possible for companies to deploy in a fully integrated, seamless experience for their employees, customers and partners.

Cisco and its partner network will now resell Jive solutions as a fully integrated component of the Cisco collaboration family. Additionally, Cisco and Jive will conduct joint product engineering to deliver further innovations and integration on the solution. Working together Cisco and Jive can work more closely to provide a complete offering for customers. See Cisco’s blog post on the Cisco and Jive relationship here.

“We still live in a business world where we have a separation of communications activities and the collaboration activities to accomplish work,” said Jens Meggers, PhD and Vice President of Cisco’s Cloud Collaboration Technology Group.  “Now, with Cisco + Jive, you have two first-class offerings coming together to provide a powerful integrated experience.”

“Cisco is one of the most well-respected companies on the planet, with hundreds of thousands of companies leveraging their real-time communication and collaboration offerings,” said Tony Zingale, CEO and chairman of Jive Software. “Together, we can bring Jive’s industry-leading collaboration platform to these customers, and help drive even deeper and more productive business outcomes across their employees, customers and partners.”

The Jive and Cisco integration provides a unified solution that enterprises around the world require today – offering one place for employees to communicate and collaborate, one place for customer communities to foster and broaden support, and one place for partners to drive business outcomes.  Enterprises can now easily go between real-time communications, like instant messages, videoconferences and online meetings, with persistent, social collaboration, like blogs, discussions, wikis, posts and online groups.

For example, Thomson Reuters’ 60,000 employees are already fully embracing and leveraging the power of Jive and Cisco. Through the integrated offering, Thomson Reuters’ employees can automatically invite people to join and launch a WebEx meeting directly from the Jive platform.  Similarly they can launch a group or 1:1 Jabber chat session directly from their Jive workflows when they want to sync with content experts versus having to log in and out of different systems.

“Jive has already driven massive productivity within Thomson Reuters by just making it simple and fast to find the people and the relevant content needed to get answers and make decisions,” said Tim Wike, senior director of Communication Platforms, Thomson Reuters. “The power of Jive and Cisco platforms allows our 60,000 employees to bring these experts directly into conversations – all from the Jive interface with one single click. The result: we are never more than a click away from collaborating in real time with our teammates using Cisco technologies. You simply can’t get this anywhere else.”

Availability
The integrated solution is now available globally from Cisco.  For more details, please see http://www.cisco.com/c/en/us/solutions/collaboration/service-listing.html.

About Jive Software
Jive (Nasdaq: JIVE) is the communication and collaboration platform for modern, mobile business. Recognized as a leader in social business by the industry’s top analyst firms, Jive’s cloud-based platform connects employees, customers and partners – transforming the way work gets done and unleashing productivity, creativity and innovation for millions of people in the world’s largest businesses.  More information can be found at www.jivesoftware.com or the Jive News Blog here.

(ANIP) Expands Product Development Collaboration with Sofgen

BAUDETTE, Minn., May 1, 2014  — ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) announced today that it has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals (“Sofgen”) for the development of an ANDA soft gel oral drug product. Sofgen will be responsible for development, manufacturing and regulatory submission of the drug and ANI will be responsible for marketing and distribution in the U.S. Prior to recent generic entry the product had branded annual U.S. sales of approximately $1 billion, per IMS Health. Financial terms of the agreement were not disclosed.

Arthur S. Przybyl, ANI’s President and CEO stated, “I am pleased to have expanded our collaboration with Sofgen through the addition of this second generic drug development project. ANI will continue to invest in both internal R&D efforts as well as external partnerships with high quality partners such as Sofgen.”

About ANI
ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.

About Sofgen
Sofgen is a dynamic company established in Florida as a specialized developer and manufacturer of niche pharmaceutical products with high barriers to entry. Sofgen is part of the Procaps Group, who has a manufacturing network with facilities throughout North and South America, with a wealth of experience in soft capsules and related delivery technologies, servicing customers within the health sector in 50 different countries around the globe. For more information, please visit our website www.sofgenpharma.com.

Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, statements about the potential benefits of the recent Merger, the Company’s plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, subject to change. You should not place undue reliance on those statements because they are subject to numerous uncertainties, risks and other factors relating to the Company’s operations and business environment and other factors, all of which are difficult to predict and many of which are beyond the Company’s control.

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may in the future face increased difficulty in importing raw materials and/or increased competition, for its Esterified Estrogen with Methyltestosterone Tablet product; competitive conditions for the Company’s other products may intensify; the Company may be required to seek the approval of the U.S. Food and Drug Administration (“FDA”) for its unapproved products or withdraw such products from the market; general business and economic conditions; the Company’s expectations regarding trends in markets for the Company’s current and planned products; the Company’s future cash flow and its ability to support its operations; the Company’s ability to obtain additional financing as needed; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of the Company’s licensees or sublicensees.

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. ANI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Arthur S. Przybyl
(218) 634-3608
arthur.przybyl@anipharmaceuticals.com

(AAWW) Announces Placement of Two Boeing 747-8 Freighters In ACMI Service for DHL Express

Atlas Air Worldwide Holdings, Inc. (Nasdaq: AAWW) today announced the placement of two Boeing 747-8 Freighters into ACMI service for DHL Express, the world’s leading international express shipping company.

The two aircraft will be operated by Atlas Air, Inc. in Polar Air Cargo Worldwide’s transpacific express network under an ACMI arrangement for the benefit of DHL Express and Polar’s other customers. The aircraft replace two Boeing 747-400 Freighters currently in ACMI service for DHL.

The state-of-the-art 747-8Fs will provide additional revenue cargo volume to serve DHL’s expanding express business. The 747-400Fs will be placed immediately into revenue service for Atlas Air.

“We are delighted to deepen our long-standing relationship with DHL and to support the strong growth of its transpacific network operations,” said William J. Flynn, President and Chief Executive Officer, Atlas Air Worldwide.

Commencement of the new ACMI service for DHL is scheduled to begin shortly. At that time, Atlas will operate a total of four 747-8Fs and five 747-400Fs in ACMI service on behalf of DHL. Atlas will also continue to operate seven Boeing 767 Freighters in CMI service for DHL.

About Atlas Air Worldwide:

Atlas Air Worldwide is the parent company of Atlas Air, Inc. (Atlas) and Titan Aviation Leasing (Titan), and is the majority shareholder of Polar Air Cargo Worldwide, Inc. (Polar). Atlas Air Worldwide also maintains a 49% interest in Global Supply Systems Limited (GSS). Through Atlas and Polar, Atlas Air Worldwide operates the world’s largest fleet of Boeing 747 freighter aircraft.

Atlas, Titan and Polar offer a range of outsourced aircraft and aviation operating services that include ACMI service – in which customers receive an aircraft, crew, maintenance and insurance on a long-term basis; CMI service, for customers that provide their own aircraft; express network and scheduled air cargo service; military cargo and passenger charters; commercial cargo and passenger charters; and dry leasing of aircraft and engines.

Atlas Air Worldwide’s press releases, SEC filings and other information can be accessed through the Company’s home page, www.atlasair.com.

(CTRX) to present at the Deutsche Bank Annual Health Care Conference

SCHAUMBURG, IL, May 1, 2014  – Catamaran (NASDAQ: CTRX) (TSX: CCT), a leading provider of technology and pharmacy benefit management (PBM) services, announces that Mike Shapiro, Chief Financial Officer, will present at the Deutsche Bank 39^th Annual Health Care Conference in Boston, Mass. Catamaran’s presentation will take place on Thursday, May 8, 2014, at 2:10 p.m. ET.

Catamaran’s presentation will be webcast live. To access the webcast, please go to: http://www.media-server.com/m/p/fxiad9nt.

About Catamaran
Catamaran, the industry’s fastest-growing pharmacy benefits manager, helps organizations and the communities they serve take control of prescription drug costs. Managing more than 350 million prescriptions each year on behalf of over 32 million members, our flexible, holistic solutions improve patient care and empower individuals to take charge of their health. Processing one in every five prescription claims in the U.S., Catamaran’s skill and scale deliver compelling financial results and sustainable improvement in the overall health of members. Catamaran is headquartered in Schaumburg, Ill., with multiple locations in the U.S. and Canada. For more information, please visit CatamaranRx.com, and for industry news and information, follow Catamaran on Twitter, @CatamaranCorp.

(MACK) Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3

MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm

Plan to submit New Drug Application in 2014

Conference Call Scheduled for 8:30 a.m. ET Today

CAMBRIDGE, Mass., May 1, 2014  — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. The NAPOLI-1 Phase 3 study was conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant (p=0.012) with a corresponding hazard ratio of 0.67. A statistically significant advantage for progression free survival was also observed in the combination arm.

The most common Grade 3 or higher adverse events in the combination arm were neutropenia (14.5%), fatigue (13.7%), diarrhea (12.8%) and vomiting (11.1%). Sepsis (3.4%) was the only serious life threatening event that occurred with a more than 2% difference between the combination arm and the control arm.

“We are excited by the results of the NAPOLI-1 study because of the critical need to help patients with this devastating illness and are moving forward as quickly as possible to get MM-398 to patients,” said Robert Mulroy, President and CEO of Merrimack. “Given that there have only been a handful of successful Phase 3 trials in pancreatic cancer in the past 25 years, it is gratifying to have the first positive Phase 3 trial in the post-gemcitabine setting. The results reinforce our confidence in our entire nanoliposomal pipeline. We are grateful for the dedication of the investigators, the research community and, most importantly, the patients and their families who bravely participated in this study.”

The Phase 3 study also examined MM-398 in a monotherapy regimen. MM-398 had a 4.9 month median overall survival as a monotherapy, but did not achieve a statistically significant survival advantage compared to the 4.2 months in the control arm. The hazard ratio for overall survival was 0.99 with a corresponding p-value of 0.942. In general, patients experienced a higher level of adverse events with the MM-398 monotherapy dose and treatment schedule compared to patients who received the combination of MM-398 with 5-FU and leucovorin.

“This demonstration of a survival benefit from the MM-398 plus 5-FU and leucovorin combination is particularly important given that we have very few treatment options for patients in this tough clinical setting,” said Daniel D. Von Hoff, M.D., F.A.C.P., global principal investigator of the NAPOLI-1 study, Chief Scientific Officer for Scottsdale Healthcare’s Virginia G. Piper Cancer Center and Distinguished Professor at Translational Genomics Research Institute (TGen).

“The Pancreatic Cancer Action Network’s goal is to double pancreatic cancer survival by 2020. The positive results of this trial demonstrate progress toward that goal in a disease for which additional treatment options are urgently needed to improve patient outcomes,” stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network. “These results also underscore the important role clinical trials play when patients are exploring their treatment options.  We applaud Merrimack’s dedication to improving the treatment landscape for this patient population, and helping us charge forward in the fight against pancreatic cancer.”

This study has been accepted for oral presentation at the European Society for Medical Oncology World Conference on Gastrointestinal Cancer being held in Barcelona, Spain on June 25-28, 2014. Merrimack expects to submit a New Drug Application to the U.S. Food and Drug Administration for the MM-398 combination regimen in 2014.

NAPOLI-1 Trial Design

NAPOLI-1 (NAnoliPOsomaL Irinotecan) is a randomized, open label Phase 3 study in patients with metastatic pancreatic cancer who received prior gemcitabine-based therapy. The study evaluated two MM-398 regimens, 80 mg/m² combined with 5-FU and leucovorin every two weeks, and 120 mg/m² as a monotherapy every three weeks. Each arm was compared to a control arm of 5-FU and leucovorin. A total of 417 patients were randomized across the three arms. Each MM-398 regimen was compared against the control arm on the primary endpoint of overall survival. Patients were enrolled at over 100 sites in North America, South America, Europe, Asia and Australia.

Merrimack to Host Conference Call

Merrimack will conduct a live conference call and webcast today, Thursday, May 1 at 8:30 a.m., Eastern Time, to discuss these top line results and provide a summary of first quarter 2014 financial results. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 37032608. A listen-only webcast of the call can be accessed in the Investors section of Merrimack’s website, http://investors.merrimackpharma.com, and a replay of the call will be archived there for six weeks following the call.

About MM-398

MM-398 (irinotecan liposome injection), also known as “nal-IRI,” is a nanoliposomal encapsulation of the chemotherapeutic irinotecan. MM-398 has demonstrated extended circulation in comparison to free irinotecan in the clinical setting. The activated form of irinotecan is SN-38, which functions by inhibiting topoisomerase I (an essential enzyme involved in DNA transcription and replication) and promoting cell death.

MM-398 is an investigational agent which is also currently being evaluated in an ongoing Phase 2 study in patients with metastatic colorectal cancer and Phase 1 studies in Ewing’s sarcoma and glioma. An additional Phase 1 clinical trial is assessing a potential companion diagnostic for MM-398 in patients with multiple cancer types to determine which patients are most likely to benefit from treatment with the drug.

Under a 2011 agreement with PharmaEngine, Inc. (Taipei, Taiwan), Merrimack consolidated the worldwide development and commercialization rights to MM-398, with PharmaEngine, Inc. retaining commercialization rights in Taiwan.

MM-398 is not approved for any indication by the U.S. Food and Drug Administration (FDA) or any other regulatory agency. Both the FDA and the European Medicines Agency have granted MM-398 orphan drug designation in metastatic pancreatic cancer.

About Pancreatic Cancer

In the United States alone, approximately 46,000 people are diagnosed with pancreatic cancer and about 40,000 patients die annually, making it the fourth most common cause of cancer death. The one year and five year mortality rates are 73 percent and 94 percent, respectively¹. Because the signs and symptoms of pancreatic cancer may not appear until the disease has spread to other sites in the body, a majority of patients are not candidates for surgery and receive chemotherapy as the mainstay of their therapy. There is no consensus on the standard of care for metastatic pancreatic cancer patients previously treated with a gemcitabine-based therapy.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack currently has six oncology therapeutics in clinical development and three additional candidates in late stage preclinical development. For more information, please visit Merrimack’s website at www.merrimackpharma.com.

¹ American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Cancer Society; 2014.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack’s strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “hope” and similar expressions. In this press release, Merrimack’s forward-looking statements include statements about the potential effectiveness and safety profile of MM-398 either alone or in combination and the expected timeline for seeking regulatory approval for the MM-398 combination regimen. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack’s companion diagnostics and other matters that could affect the availability or commercial potential of Merrimack’s drug candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack’s views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack’s business in general, see the “Risk Factors” section of Merrimack’s Annual Report on Form 10-K filed with theSecurities and Exchange Commission(SEC) onMarch 4, 2014and other reports Merrimack files with theSEC.

CONTACT: Investor Contact:
         Geoffrey Grande, CFA
         Merrimack
         617-441-7602
         ggrande@merrimackpharma.com

         Media Contacts:
         Kathleen Gallagher
         Merrimack
         617-441-1043
         kgallagher@merrimackpharma.com

         Liz Bryan
         Spectrum
         202-955-6222
         lbryan@spectrumscience.com